FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Soft Tissue Sarcoma

Therapeutic area intelligence for Soft Tissue Sarcoma with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

Abemaciclib →

Phase →

Recent signals(3)

ClinicalJuly 20, 2026

Phase I/II Trial of Proton-SFRT and Standard Radiation for Retroperitoneal Soft Tissue Sarcoma

A phase I/II trial is investigating the efficacy and safety of proton-spatially fractionated radiotherapy combined with standard radiation therapy for newly diagnosed retroperitoneal soft tissue sarcoma.

ClinicalJuly 11, 2026

Immunotherapy Shows Promise in Treating Soft-Tissue Sarcoma with Combination Strategies

Soft-tissue sarcoma (STS) is primarily immune-cold, but combination therapies and neoadjuvant strategies show promise in enhancing checkpoint inhibition responses.

ClinicalJune 21, 2026

Phase I/II Trial of Abemaciclib with Gemcitabine for Advanced Soft Tissue Sarcoma

A phase I/II trial is evaluating the safety and efficacy of abemaciclib combined with gemcitabine versus gemcitabine with docetaxel in patients with advanced soft tissue sarcoma.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.